Physician profile
Geoffrey Kaplan
NPI 1174597140
$792.34
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $154 · 2021: $35.39 · 2022: $168.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $168.01 | 2019-2020 | |
| Alcon Vision LLC | $134.91 | 2019-2022 | |
| Shire North American Group INC | $122.76 | 2019 | |
| Aerie Pharmaceuticals, INC. | $116.36 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $83.39 | 2019-2021 | |
| Abbvie INC. | $50.24 | 2022 | |
| Genentech USA, INC. | $39.61 | 2019-2021 | |
| Allergan, INC. | $34.87 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $26.73 | 2019 | |
| Genmab U.S., INC. | $15.46 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.